Lineage Cell Therapeutics(LCTX) - 2025 Q2 - Quarterly Results

LINEAGE CELL THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE CARLSBAD, CA – August 12, 2025 - Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical- stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious neurological and ophthalmic conditions, today reported its second quarter 2025 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these result ...